F1ash, bad day for all involved, patients and competing drugs and the like IMO. Always wise not to invest more than one can afford to lose in any of these and starting to look like the better risk is awaiting a 2B positive top line before nibbling in. Regardless I think the biggest takeaway is and I've posted this multiple times, is AD is so misunderstood. I do think it will take a novel approach to give significant relief but even knowing your drug is novel doesn't necessarily translate in trials no matter how bad we(I) hoped it would. Even alzheimer's "experts" don't completely understand the disease as witnessed by BP failure with all their money and resources. The reason I liked this one was the similarity between synapses in animals and humans as opposed to creating a plaque brain in animals that don't get alzheimer's and making comparisons. Until there is a complete understanding (and there may never be) of AD, they'll all be risky as it gets IMO.
News 
Market Data 
Discover 
AI
